Research Analysts Issue Forecasts for RIGL FY2026 Earnings

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) – Equities research analysts at HC Wainwright dropped their FY2026 EPS estimates for Rigel Pharmaceuticals in a report issued on Tuesday, January 13th. HC Wainwright analyst J. Pantginis now expects that the biotechnology company will earn $3.14 per share for the year, down from their prior forecast of $5.19. HC Wainwright has a “Buy” rating and a $57.00 price target on the stock. The consensus estimate for Rigel Pharmaceuticals’ current full-year earnings is $0.22 per share. HC Wainwright also issued estimates for Rigel Pharmaceuticals’ FY2027 earnings at $3.92 EPS and FY2028 earnings at $4.73 EPS.

Rigel Pharmaceuticals (NASDAQ:RIGL) last released its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $1.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.93 by $0.53. The business had revenue of $69.46 million for the quarter, compared to analyst estimates of $61.88 million. Rigel Pharmaceuticals had a net margin of 40.17% and a return on equity of 204.70%.

A number of other equities research analysts have also recently commented on RIGL. Zacks Research upgraded Rigel Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, January 5th. Weiss Ratings restated a “hold (c+)” rating on shares of Rigel Pharmaceuticals in a research note on Wednesday, October 8th. Wall Street Zen raised shares of Rigel Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Sunday, December 21st. Cantor Fitzgerald lifted their target price on shares of Rigel Pharmaceuticals from $32.00 to $38.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 5th. Finally, Jefferies Financial Group raised shares of Rigel Pharmaceuticals from a “hold” rating to a “buy” rating and boosted their target price for the stock from $23.00 to $42.00 in a research report on Wednesday, November 5th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $43.20.

Rigel Pharmaceuticals Stock Up 3.1%

Rigel Pharmaceuticals stock opened at $39.12 on Thursday. Rigel Pharmaceuticals has a 1-year low of $15.50 and a 1-year high of $52.24. The business has a fifty day moving average price of $43.23 and a 200-day moving average price of $34.39. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.28 and a quick ratio of 2.14. The stock has a market capitalization of $710.07 million, a price-to-earnings ratio of 6.34 and a beta of 1.11.

Institutional Investors Weigh In On Rigel Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of RIGL. Hennion & Walsh Asset Management Inc. purchased a new stake in Rigel Pharmaceuticals in the fourth quarter valued at approximately $2,235,000. SG Americas Securities LLC raised its position in Rigel Pharmaceuticals by 82.0% during the 4th quarter. SG Americas Securities LLC now owns 12,768 shares of the biotechnology company’s stock worth $547,000 after buying an additional 5,754 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in Rigel Pharmaceuticals by 251.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 34,960 shares of the biotechnology company’s stock valued at $990,000 after acquiring an additional 25,013 shares during the period. IFP Advisors Inc acquired a new stake in Rigel Pharmaceuticals during the 3rd quarter valued at approximately $55,000. Finally, Caitong International Asset Management Co. Ltd purchased a new stake in shares of Rigel Pharmaceuticals in the 3rd quarter valued at $62,000. Institutional investors and hedge funds own 66.23% of the company’s stock.

Rigel Pharmaceuticals Company Profile

Rigel Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. Founded in 2003, Rigel focuses on the discovery, development and commercialization of novel small molecule therapeutics targeting immune, hematologic and oncologic diseases. Leveraging a proprietary chemistry platform and expertise in signal transduction pathways, the company aims to address significant unmet medical needs in both rare and common disorders.

Rigel’s lead product, fostamatinib (commercially known as Tavalisse®), is an oral spleen tyrosine kinase (SYK) inhibitor approved in the United States for the treatment of adult patients with chronic immune thrombocytopenia (ITP).